Pharma Should Include ‘Heterogeneous Health Data’ In EU Regulatory & HTA Dossiers

Real-world data collected from a wide range of sources, such as wearable devices and public databases, can be used by pharmaceutical companies to boost their marketing authorization and health technology assessment applications, a regulatory policy expert from Sanofi says.